According to the findings of a recent Future Market Insights (FMI) study, the global Ibuprofen API Market Revenue will exceed US$ 626.2 Million in 2022 and will grow at a CAGR of 3% to reach US$ 772.2 Million by 2029. The key drivers of the Ibuprofen API market are the continued need for low-cost nonsteroidal anti-inflammatory medicines (NSAID), as well as the size and age of manufacturing facilities.
The rise of low-cost medication manufacturers in various nations, as well as the availability of API medications, particularly in developing countries, are all driving expansion in the ibuprofen API market.
Get Sample Report + Related Graphs & Charts@ https://www.futuremarketinsights.com/reports/sample/rep-gb-11260
The pharmaceutical API industry is experiencing significant supply and demand restrictions for Ibuprofen API, with major ibuprofen API producers stopping production and a supply chain disruption in China exacerbated by decreasing sales in India.
The volatility in Ibuprofen API is caused by a smaller number of competitors, a lower utilisation ratio, a lower margin level, new higher-value opportunities in complex combinations and high-grade API, the pace of FDA facility inspections, and ramping up production capacity through mergers and consolidation.
A wide variety of ailments, including cardiovascular disease, infectious diseases, diabetes, and kidney difficulties, have a high global prevalence. As a result, the increased prevalence of a wide range of diseases across all age groups, as well as their global impact, fuels demand for medication research and the pharmaceutical business.
High throughput, bioinformatics, and combinatorial chemistry are examples of modern technologies that are being used to improve drug candidate identification. Drug development has evolved dramatically as technology has advanced, making the process more complex, precise, and time-consuming. High-throughput screening is one of the most extensively utilised drug discovery technologies due to automation, multi-detector readers, imaging equipment, and software.
Last few days to get reports at discounted prices, offer expires soon!
Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-11260
Key Takeaways of Ibuprofen API Market Study
- Up-scaling is the main strategy stated for fulfilling demand in the Ibuprofen API sector, with a greater emphasis on relieving pressure on the supply chain due to the demand gap.
- The majority of anti-inflammatory medications are produced in Asia, particularly in China and India. Approximately 80% of all anti-inflammatory APIs are created in India and China, with the majority of these APIs being outsourced to other developed nations such as North America and Europe.
- Ibuprofen API’s high upfront cost and low margin level have resulted in a 20-30% price increase in final medicine formulations and reduced sales in the previous year.
- The Ibuprofen API industry is highly consolidated, with top producers controlling around 90% of the market value. As a result, the increased interest of CMOs and large-scale API makers is expected to drive the ibuprofen API market’s value generation.
- Contract Manufacturing Organizations are predicted to produce considerable income pockets because to their higher volume handling in contrast to pharmaceutical firms, as well as their higher manufacturing capabilities and price advantage over pharmaceutical organisations.
- The growing patient pool taking non-controlled medications like OTC is also driving the increase in in-house ibuprofen API consumption in South and East Asia.
Lower labour cost and abundant availability of raw materials required for ibuprofen API are among the key factors fuelling the growth of the ibuprofen API market in South Asia. In addition, favourable regulatory support to establish ibuprofen API manufacturing businesses, and lower taxation policies are boosting the growth of the East and South Asia ibuprofen API market.
Expand Operations in the Future – To Get Requisite Details, Ask for a Custom Report@ https://www.futuremarketinsights.com/customization-available/rep-gb-11260
Capacity Expansion, and Strategic Mergers & Acquisitions to Widen Regional Presence
Leading players in the ibuprofen API market – SI Group, Inc., BASF SE, Hubei Biocause Pharmaceutical Co., Ltd. (BIOCAUSE Inc.), IOL Chemicals, Sino-US Zibo Xinhua-Perrigo Pharmaceutical Co., Ltd., and Solara Active Pharma Sciences Limited – are focusing on business expansions by mergers, joint ventures, distribution agreements and capturing the untapped potential of the Ibuprofen API market.
- IOL Chemicals, the largest Indian Ibuprofen API manufacturer, increased its manufacturing capacity to 12000 MT in 2018 from 7500 MT previously. IOL Chemicals is covering the demand-supply gap that is widening as a result of China’s strict regulatory reform. This decision may benefit Indian firms trying to expand their presence in the Ibuprofen API market.
- Solara Active Pharma Sciences Limited acquired Strides and Sequent’s Ibuprofen API assets in 2018, allowing the company to capture a portfolio of specialist niches of the Ibuprofen API industry.
- Granules India Ltd (GIL) and Hubei Biocause Heilen Pharmaceutical Co. Ltd. have a manufacturing facility in Jingmen, China. According to a recent debate, Granules India Ltd (GIL) intends to exit the joint venture.
Additionally, current acquisitions are focused on capacity expansion, and manufacturing capabilities of existing Ibuprofen API players to gain competitiveness and accelerate revenue growth in the market landscape.
Key Segments of Ibuprofen API Industry Survey
Ibuprofen API Market by End User:
- Contract Manufacturing Organizations
- Pharmaceutical Companies
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs
